Anesthetic Management for Open Abdominal Aortic Aneurysm (AAA) Repair in a 50-Year-Old Patient

1. Understanding the Procedure

2. Preoperative Assessment and Optimization

A. Cardiovascular Evaluation

• History: Screen for angina, prior MI, TIA, claudication, dyspnea, peripheral edema
• Physical examination: Assess for S4 gallop, jugular venous distension, rales, peripheral edema, absent/diminished pulses
• ECG: Mandatory as baseline (12-lead); look for prior ischemic changes
• Echocardiography: Required if LV dysfunction documented, worsening symptoms, or function not assessed in the past year; or dyspnea of unknown origin
• Cardiac stress testing: Per ACC/AHA 2014 guidelines - assess functional capacity (METs), proceed if >4 METs without symptoms; further testing only if it will change management
• Cardiac biomarkers: Troponin I, NT-proBNP, CRP, cystatin C - increasingly used for perioperative risk stratification
• Coronary artery calcium scoring or CIMT may add risk information

B. Pulmonary Assessment

C. Renal Function

D. Laboratory Investigations

E. Medication Management

• Beta-blockers: If already on, continue; do NOT abruptly discontinue (risk of rebound). Starting de novo beta-blockade is controversial - the DECREASE trial findings are disputed; start only if time allows for dose titration over weeks
• Statins: Continue perioperatively; discontinuation is associated with increased cardiac events. Fluvastatin has been studied specifically in vascular surgery patients and is cardioprotective
• ACE inhibitors / ARBs: Hold on the morning of surgery to prevent refractory intraoperative hypotension
• Antiplatelet agents: Aspirin is generally continued; discuss with surgeon

3. Anesthetic Plan

A. Choice of Anesthetic Technique

B. Monitoring

C. Vascular Access

• Two large-bore peripheral IVs (14-16G) for rapid volume resuscitation
• Central venous line (internal jugular or subclavian)
• Cell salvage (autotransfusion): Mandatory - significantly reduces allogeneic transfusion requirements in open AAA repair

D. Epidural Catheter

• Place before induction (T8-T10 level for infrarenal AAA)
• Confirm coagulation studies are normal before placement
• Epidural provides: intraoperative analgesia, reduced volatile agent requirement, excellent postoperative analgesia
• Risk: Heparinization is required intraoperatively; follow ASRA guidelines (epidural catheter should be placed >12 hours before systemic heparinization; removal only when ACT normalizes)

4. Induction of Anesthesia

• Pre-oxygenation: 3-5 minutes with 100% O2
• Rapid sequence induction if full stomach or standard induction
• Induction agents: Etomidate (0.3 mg/kg) preferred in patients with limited cardiac reserve (minimal hemodynamic effect); propofol (1-2 mg/kg) if hemodynamically stable
• Opioid: Fentanyl (2-5 mcg/kg) or remifentanil infusion to blunt laryngoscopy response
• Muscle relaxant: Succinylcholine for RSI; rocuronium (1.2 mg/kg) with sugammadex availability; vecuronium/cisatracurium for maintenance
• Airway: Endotracheal intubation with cuff (secured airway mandatory for open surgery)
• Have vasopressors ready (phenylephrine, vasopressin) for post-induction hypotension

5. Intraoperative Management

A. Maintenance

• Balanced technique: Low-dose volatile agent (isoflurane or sevoflurane - 0.5-1 MAC) + epidural local anesthetic/opioid + IV opioid if needed
• Ventilation: Controlled ventilation, tidal volume 6-8 mL/kg ideal body weight; PEEP 5 cmH2O; FiO2 0.4-0.5 (higher during cross-clamp)
• Temperature management: Active warming (forced-air blanket for upper body, warmed IV fluids); significant heat loss occurs through open abdomen

B. The Aortic Cross-Clamp: The Critical Physiologic Event

• Sudden increase in afterload (SVR increases by 40-100%)
• Increased cardiac preload (blood redistribution)
• Hypertension - especially severe with suprarenal clamp
• Risk of myocardial ischemia and LV failure in patients with poor cardiac reserve
• Management: Vasodilators (nitroprusside, nitroglycerin), volatile agent titration upward, communicate with surgical team

• Sudden drop in SVR - hypotension and cardiovascular collapse risk
• Reactive hyperemia in ischemic limbs
• Release of acidic metabolites, potassium, and inflammatory mediators
• Management:
  • Volume loading before unclamping (communicate with surgeon for gradual unclamping)
  • Vasopressors ready (phenylephrine, norepinephrine)
  • Sodium bicarbonate for metabolic acidosis if severe
  • Calcium gluconate for hyperkalaemia

C. Fluid and Blood Management

• Goal-directed fluid therapy: TEE or arterial waveform analysis to guide resuscitation
• Anticipate large fluid shifts (3rd space losses, blood loss)
• Target: urine output >0.5 mL/kg/hr
• Transfusion triggers: Hgb <7-8 g/dL generally, but higher threshold (8-9 g/dL) in high cardiac risk patients
• Cell salvage blood returned as available
• In massive hemorrhage: activate massive transfusion protocol (MTP) - ratio of pRBC:FFP:platelets = 1:1:1
• Mannitol 0.5-1 g/kg IV given before infrarenal cross-clamp to promote diuresis and renal protection

D. Renal Protection

• The cross-clamp level is critical: infrarenal clamping - renal perfusion maintained; suprarenal clamping - renal ischemia is a major concern
• Maintain adequate MAP (>65-70 mmHg), urine output, and consider mannitol
• Avoid nephrotoxins (NSAIDs, aminoglycosides, contrast)
• No proven pharmacologic renoprotectant currently - dopamine at "renal doses" is not evidence-based

E. Spinal Cord Protection (Suprarenal/Thoracoabdominal Cases)

• For extensive suprarenal or thoracoabdominal aneurysms: risk of spinal cord ischemia and paraplegia
• Strategies: CSF drainage (maintain CSF pressure <10 mmHg), SSEP/MEP monitoring, maintain MAP >80 mmHg, minimize clamp time, selective spinal artery reimplantation

6. Specific Challenges in a 50-Year-Old Patient

• Connective tissue disorders (Marfan syndrome, Loeys-Dietz, Ehlers-Danlos) - check FBN1/TGFBR2/COL3A1 status
• Underlying genetic aortopathy - implications for family screening
• Higher life expectancy means long-term durability of repair matters more
• Physiologic reserve is generally better than elderly patients - may tolerate hemodynamic swings more easily

7. Postoperative Management

A. ICU Admission

• All open AAA repairs should be admitted to the surgical ICU postoperatively
• Continued invasive monitoring (arterial line, CVP)
• Mechanical ventilation may be needed for 4-12 hours depending on fluid status, temperature, and hemodynamic stability

B. Pain Management

• Thoracic epidural: most effective for open abdominal surgery; reduces pulmonary complications
• Epidural running: dilute local anesthetic (bupivacaine 0.0625-0.125%) + opioid (fentanyl or hydromorphone)
• Ensure epidural catheter removal is timed appropriately around anticoagulation

C. Potential Complications to Monitor

8. Summary: Key Anesthetic Priorities

1. Preoperative cardiac optimization is the most important step
2. Invasive monitoring early (A-line before induction)
3. Hemodynamic stability at induction and throughout (prevent surges that stress the aneurysm wall)
4. Cross-clamp physiology - prepare for hypertension at application, hypotension at release
5. Epidural analgesia - plan timing around heparinization carefully
6. Renal protection - fluid management, mannitol, avoid nephrotoxins
7. Blood conservation - cell saver, transfusion triggers, MTP protocol
8. Postoperative ICU - aggressive monitoring for MACE, AKI, bowel ischemia

Anesthetic Management of a 50-Year-Old Patient Posted for Open Abdominal Aortic Aneurysm (AAA) Repair

Definition and Surgical Context (0.5 marks)

Preoperative Assessment (2 marks)

Cardiovascular (most important)

• Vascular surgery carries the highest perioperative MACE risk of all non-cardiac surgeries
• Detailed history: angina, prior MI, TIA, dyspnea, claudication
• Examination: S4 gallop, JVD, peripheral edema, pulse deficits
• 12-lead ECG - mandatory baseline
• Echocardiography - if LV dysfunction documented, worsening symptoms, or dyspnea of unknown origin
• Stress testing - only if it will change management; assess functional capacity (>4 METs = low risk)
• Biomarkers - troponin, NT-proBNP for risk stratification
• Active ACS, decompensated HF, severe aortic stenosis - must be corrected before elective surgery

Pulmonary

• Strong smoking history expected; screen for COPD, OSA
• Optimize bronchodilators; advise smoking cessation ≥4-8 weeks preoperatively

Renal

• Baseline creatinine/eGFR essential - elevated risk of postoperative AKI
• Avoid nephrotoxins; ensure pre-op hydration

Investigations

Medication Optimization

• Beta-blockers: Continue if already prescribed; do NOT abruptly stop
• Statins: Continue perioperatively (cardioprotective; withdrawal increases cardiac events)
• ACE inhibitors/ARBs: Hold on morning of surgery (prevents refractory intraoperative hypotension)
• Aspirin: Generally continue; discuss with surgeon

Anesthetic Plan (1 mark)

• Combined technique offers superior postoperative pain control, reduced pulmonary complications, lower opioid requirement, and sympatholysis
• Epidural placed at T8-T10 level before induction
• Coagulation studies must be normal before placement; observe ASRA timing guidelines around heparinization

Monitoring (1 mark)

Induction (1 mark)

• Preoxygenation 3-5 minutes (100% O2)
• Etomidate 0.3 mg/kg (preferred - cardiovascular stability) or propofol if hemodynamically stable
• Fentanyl 2-5 mcg/kg to blunt laryngoscopy response
• Rocuronium 1.2 mg/kg (sugammadex available) or succinylcholine for RSI
• Endotracheal intubation (secure airway mandatory)
• Vasopressors drawn up and ready (phenylephrine, norepinephrine) - post-induction hypotension is common

Intraoperative Management (2.5 marks)

Maintenance

• Balanced technique: low-dose volatile agent (isoflurane/sevoflurane 0.5-1 MAC) + epidural infusion
• Controlled ventilation: TV 6-8 mL/kg IBW, PEEP 5 cmH2O
• Active warming throughout (forced-air blanket, warmed IV fluids)

The Aortic Cross-Clamp - The Critical Event

• Sudden ↑ afterload (SVR increases 40-100%), ↑ preload, hypertension
• Risk of myocardial ischemia/LV failure
• Management: Vasodilators (nitroprusside/GTN), ↑ volatile agent

• Sudden ↓ SVR → severe hypotension, cardiovascular collapse
• Release of acidic metabolites, K+, inflammatory mediators
• Management:
  • Pre-emptive volume loading; request gradual, staged unclamping from surgeon
  • Vasopressors (norepinephrine)
  • Sodium bicarbonate for metabolic acidosis
  • Calcium chloride for hyperkalaemia

Heparinization

• Systemic heparin 100 units/kg given 5 min before cross-clamp application
• Monitor with ACT (target >250-300 sec)
• Reversal: Protamine 1 mg per 100 units heparin given after clamp release and anastomosis

Fluid and Blood Management

• Goal-directed fluid therapy guided by TEE or arterial waveform analysis
• Target urine output >0.5 mL/kg/hr
• Transfusion trigger: Hgb <7 g/dL (higher threshold 8-9 g/dL in cardiac risk patients)
• Massive transfusion protocol if needed: pRBC:FFP:Platelets = 1:1:1

Renal Protection

• Maintain MAP >65-70 mmHg
• Mannitol 0.5-1 g/kg IV before infrarenal cross-clamp application
• Avoid nephrotoxins; ensure adequate hydration
• Suprarenal clamping carries far higher AKI risk - minimize clamp time

Postoperative Management (1 mark)

ICU Admission (Mandatory)

• Continued invasive monitoring (A-line, CVP)
• Controlled ventilation for 4-12 hours if hypothermic, hemodynamically unstable, or large fluid balance

Pain Management

• Thoracic epidural: dilute bupivacaine (0.0625-0.125%) + opioid (fentanyl/hydromorphone)
• Epidural removal only when anticoagulation is reversed (follow ASRA guidelines)

Complications to Monitor

Summary - Five Core Anesthetic Priorities (1 mark)

1. Preoperative cardiac optimization - most critical step; correct reversible ischemia
2. Early invasive monitoring - A-line before induction, TEE intraoperatively
3. Cross-clamp physiology - prepare for hypertension on application, hypotension on release
4. Epidural timing around heparin - follow ASRA guidelines strictly
5. Postoperative ICU - vigilance for MACE, AKI, bowel and limb ischemia

References: Barash, Cullen & Stoelting's Clinical Anesthesia 9e (pp. 3402-3452); Miller's Anesthesia 9e; Morgan & Mikhail's Clinical Anesthesiology